Diagnostic Biomarkers in Metabolomics
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. A biomarker reveals further information to presently existing clinical and pathological analysis. It facilitates screening and detecting the disease, monitoring the progression of the disease, and predicting the diagnosis and survival after clinical intervention. A biomarker can also be used to evaluate the process of drug development and optimally to improve the efficacy and safety of disease treatment by enabling physicians to tailor treatment for individual patients. These emerging biomarkers will be beneficial and critical in developing new and clinically reliable indicators that will have a high specificity for the diagnosis.
- Metabolite platform for validation of biomarkers
- Biomarkers in drug development
- Disease related biomarkers
- Imaging biomarkers
- Metabolomics in biomarker discovery
Related Conference of Diagnostic Biomarkers in Metabolomics
Diagnostic Biomarkers in Metabolomics Conference Speakers
Recommended Sessions
- Analytical Techniques in Metabolomics
- Cancer Metabolomics
- Clinical and Precision Medicine Metabolomics
- Computational Methodologies
- Diagnostic Biomarkers in Metabolomics
- Disease-Focused Research in Metabolomics
- Edibilomics
- Lipidomics
- Metabolic Modelling and Synthetic Biology
- Metabolomic Devices
- Metabolomic Syndrome
- Metabolomics
- Metabolomics in Drug Discovery
- Plant and Environmental Metabolomics
- Recent Advancements in Metabolomics
- Systems Biology
- Transcriptomics and Proteomics
Related Journals
Are you interested in
- 3-D Structure Determination - Structural Biology 2025 (Germany)
- Advancements in structural Biology - Structural Biology 2025 (Germany)
- Biochemistry - Glycobiology 2025 (Germany)
- Biochemistry and Biophysics - Structural Biology 2025 (Germany)
- Computational Approach in Structural Biology - Structural Biology 2025 (Germany)
- Drug Designing and Biomarkers - Structural Biology 2025 (Germany)
- Evolution of Glycan Diversity - Glycobiology 2025 (Germany)
- Frontiers in Structural Biology - Structural Biology 2025 (Germany)
- Gene regulation and Cell Signalling - Structural Biology 2025 (Germany)
- Genomics and Metabolomics - Glycobiology 2025 (Germany)
- Glycans in Diseases and Therapeutics - Glycobiology 2025 (Germany)
- Glycans in Drug Design - Glycobiology 2025 (Germany)
- Glycan’s - Glycobiology 2025 (Germany)
- Glycobiology - Glycobiology 2025 (Germany)
- Glycochemistry - Glycobiology 2025 (Germany)
- Glycoimmunology - Glycobiology 2025 (Germany)
- Glycoinformatics - Glycobiology 2025 (Germany)
- Glycolipids and Glycopeptides - Glycobiology 2025 (Germany)
- Glyconeurobiology - Glycobiology 2025 (Germany)
- Glycopathology - Glycobiology 2025 (Germany)
- Glycosience - Glycobiology 2025 (Germany)
- Hybrid approaches in Structure prediction - Structural Biology 2025 (Germany)
- Molecular Biology - Structural Biology 2025 (Germany)
- Molecular biology techniques - Structural Biology 2025 (Germany)
- Molecular Modelling and Dynamics - Structural Biology 2025 (Germany)
- Proteoglycan and Sialic acid - Glycobiology 2025 (Germany)
- Proteomics and Genomics - Structural Biology 2025 (Germany)
- Recent Advances in Glycobiology - Glycobiology 2025 (Germany)
- Sequencing Analysis - Structural Biology 2025 (Germany)
- Structural Bioinformatics - Structural Biology 2025 (Germany)
- Structural Biology - Structural Biology 2025 (Germany)
- Structural Biology Databases - Structural Biology 2025 (Germany)
- Structural Biology in Cancer Research - Structural Biology 2025 (Germany)
- Structural Enzymology - Structural Biology 2025 (Germany)
- Synthesis and Biological Role of Glycans - Glycobiology 2025 (Germany)